胃潰瘍の世界市場レポート 2025年

胃潰瘍市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.5％で56億4,000万米ドルに成長します。予測期間の成長は、診断技術の向上、不健康な食習慣の採用、プロトンポンプ阻害薬（PPI）を含む治療オプションの進歩、疾病負担の増加に寄与する高齢化、新興市場におけるヘルスケアインフラの拡大などに起因すると考えられます。予測期間における主な動向としては、有効性を高めるための併用療法へのシフト、低侵襲治療手技への嗜好の高まり、疾患管理におけるデジタルヘルスソリューションの統合、一般用医薬品（OTC）潰瘍治療薬の需要増加、潰瘍治療における個別化医療アプローチの拡大などが挙げられます。

老年人口の増加は、今後数年間の胃潰瘍市場の成長を牽引すると予想されます。老年人口とは、一般的に65歳以上の高齢者を指し、加齢に伴う特有の健康課題に直面しています。この増加の主な原因は、世界の多くの地域で出生率が低下していることに加え、平均寿命の延長につながったヘルスケアの進歩にあります。胃潰瘍は、合併症のリスクを高める非ステロイド性抗炎症薬の頻繁な使用と粘膜保護の低下により、高齢者に多く見られます。例えば、2024年1月、米国の非営利団体である人口問題研究所（PRB）は、65歳以上の米国人の人口が2022年の5,800万人から2050年には8,200万人に47％増加する見込みであると報告しています。さらに、この年齢層が総人口に占める割合は17％から23％に上昇すると予測されており、米国の高齢化傾向が顕著であることを浮き彫りにしています。こうした予測は、さまざまな分野で高齢者のヘルスケアニーズに対応する必要性が高まっていることを強調しています。このように、高齢者人口の増加が胃潰瘍市場の成長を牽引しています。

胃潰瘍市場の主な企業は、治療効果を高め副作用を最小限に抑えるため、新製剤などの革新的な製品の開発に注力しています。新剤形とは、有効性、安全性、患者の服薬アドヒアランスを高めることを目的とした、有効成分、ドラッグデリバリー、剤形の新しい組み合わせによる医薬品の創製を指します。例えば、2024年6月、インドの製薬メーカーであるアクムス・ドラッグ・アンド・ファーマシューティカルズ社は、ラベプラゾール＋レボスルピリドSRカプセルを発売しました。このカプセルは、胃食道逆流症（GERD）やその他の消化管（GIT）障害などの症状を改善するよう設計されています。プロトンポンプ阻害剤とプロキネティック製剤の組み合わせにより、GERDや胃潰瘍などの胃腸障害を効果的に治療します。この製剤は、胃酸分泌を減少させるだけでなく、胃の運動を改善し、胸やけや消化不良などの症状を総合的に緩和します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界胃潰瘍PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の胃潰瘍市場：成長率分析
• 世界の胃潰瘍市場の実績：規模と成長, 2019-2024
• 世界の胃潰瘍市場の予測：規模と成長, 2024-2029, 2034F
• 世界胃潰瘍総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の胃潰瘍市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• プロトンポンプ阻害剤（PPI）
• H2拮抗薬
• 制酸剤
• 抗生物質
• 細胞保護剤
• その他の薬物クラス
• 世界の胃潰瘍市場診断別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 便検査
• 内視鏡検査
• 画像検査
• コンピュータ断層撮影（CT）スキャン
• X線
• 血液検査
• その他の診断
• 世界の胃潰瘍市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界の胃潰瘍市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• その他の流通チャネル
• 世界の胃潰瘍市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• ホームケア
• その他のエンドユーザー
• 世界の胃潰瘍市場プロトンポンプ阻害剤（PPI）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• オメプラゾール
• ランソプラゾール
• パントプラゾール
• エソメプラゾール
• ラベプラゾール
• 世界の胃潰瘍市場H2拮抗薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ラニチジン
• ファモチジン
• シメチジン
• ニザチジン
• 世界の胃潰瘍市場制酸剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 炭酸カルシウム
• 水酸化マグネシウム
• 水酸化アルミニウム
• 重炭酸ナトリウム
• 世界の胃潰瘍市場抗生物質の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アモキシシリン
• クラリスロマイシン
• メトロニダゾール
• テトラサイクリン
• 世界の胃潰瘍市場細胞保護剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• スクラルファート
• ミソプロストール
• 次サリチル酸ビスマス
• 世界の胃潰瘍市場、その他の薬物クラスのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• プロスタグランジン類似体
• 消化管運動促進剤
• ハーブ療法と代替療法
• 併用療法

第7章 地域別・国別分析

• 世界の胃潰瘍市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の胃潰瘍市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 胃潰瘍市場：競合情勢
• 胃潰瘍市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Abbott Laboratories
• Novartis AG
• GlaxoSmithKline plc
• Takeda Pharmaceutical Co. Ltd
• Amgen Inc.
• Boehringer Ingelheim
• Viatris Inc.
• Daiichi Sankyo Company Limited
• Eisai Co. Ltd
• Cadila Pharmaceuticals
• Dr. Reddy's Laboratories Ltd.
• Hikma Pharmaceuticals PLC
• Lupin Limited
• Yuhan Corporation
• Daewoong Pharmaceutical Co. Ltd

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 胃潰瘍市場2029：新たな機会を提供する国
• 胃潰瘍市場2029：新たな機会を提供するセグメント
• 胃潰瘍市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Gastric ulcers, also known as peptic ulcers, are open sores on the stomach's inner lining caused by the corrosive action of stomach acid. They often result in burning stomach pain, indigestion, and discomfort. These ulcers typically arise from an imbalance between stomach acid, the enzyme pepsin, and the protective mucosal barrier lining the stomach and duodenum.

The primary drug classes used to treat gastric ulcers include proton pump inhibitors (PPIs), H2 antagonists, antacids, antibiotics, cytoprotective agents, and others. Proton pump inhibitors are medications that reduce stomach acid production by inhibiting the proton pump enzyme in gastric cells. Gastric ulcers can be diagnosed through stool tests, endoscopies, imaging tests, computed tomography (CT) scans, X-rays, blood tests, and other methods. Treatment routes include oral and parenteral administration, among others. Distribution channels primarily consist of hospital pharmacies, retail pharmacies, and online pharmacies, and the treatments are utilized by various end-users such as hospitals, specialty clinics, and homecare settings.

The gastric ulcers market research report is one of a series of new reports from The Business Research Company that provides gastric ulcers market statistics, including gastric ulcers industry global market size, regional shares, competitors with a gastric ulcers market share, detailed gastric ulcers market segments, market trends and opportunities, and any further data you may need to thrive in the gastric ulcers industry. This gastric ulcers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gastric ulcers market size has grown strongly in recent years. It will grow from $4.29 billion in 2024 to $4.54 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to the rising prevalence of helicobacter pylori infections, increasing use of nonsteroidal anti-inflammatory drugs (NSAIDs), growing geriatric population globally, rising awareness campaigns for gastric ulcer prevention and increasing incidence of stress-related disorders.

The gastric ulcers market size is expected to see strong growth in the next few years. It will grow to $5.64 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to improvements in diagnostic techniques, adoption of unhealthy dietary habits, advancements in treatment options, including proton pump inhibitors (PPIs), aging population contributing to higher disease burden and expansion of healthcare infrastructure in emerging markets. Major trends in the forecast period include shift towards combination therapies for enhanced efficacy, growing preference for minimally invasive treatment procedures, integration of digital health solutions in disease management, rising demand for over-the-counter (OTC) ulcer medications and expansion of personalized medicine approaches in ulcer treatment.

The growing geriatric population is expected to drive the growth of the gastric ulcers market in the coming years. The geriatric population refers to individuals typically aged 65 and older, who face unique health challenges associated with aging. This increase is primarily due to advancements in healthcare, which have led to longer life expectancies, alongside declining birth rates in many regions worldwide. Gastric ulcers are more common among the elderly due to the frequent use of NSAIDs and reduced mucosal protection, both of which heighten the risk of complications. For example, in January 2024, the Population Reference Bureau (PRB), a US-based non-profit organization, reported that the population of Americans aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, a 47% increase. Moreover, this age group's share of the total population is projected to rise from 17% to 23%, highlighting a significant aging trend in the U.S. population. These projections emphasize the growing need to address the healthcare needs of older adults across various sectors. As such, the increasing geriatric population is driving the growth of the gastric ulcers market.

Key companies in the gastric ulcer market are focusing on developing innovative products, such as new drug formulations, to improve treatment effectiveness and minimize side effects. New formulation drugs involve the creation of medications with novel combinations of active ingredients, delivery methods, or dosage forms aimed at enhancing their efficacy, safety, and patient adherence. For example, in June 2024, Akums Drugs and Pharmaceuticals Ltd., an India-based pharmaceutical manufacturer, introduced Rabeprazole + Levosulpiride SR Capsules. These capsules are designed to provide better relief for conditions like gastro-oesophageal reflux disease (GERD) and other gastrointestinal tract (GIT) disorders. The combination of a proton pump inhibitor and a prokinetic agent effectively treats gastrointestinal issues, including GERD and gastric ulcers. This formulation not only decreases gastric acid secretion but also improves gastric motility, offering comprehensive relief from symptoms such as heartburn and indigestion.

In May 2022, Dr. Reddy's Laboratories partnered with HK Inno.N. Corporation to supply and commercialize Tegoprazan, a novel molecule for gastrointestinal diseases, in India and six key emerging markets. Under this partnership, HK Inno.N. will manufacture and supply Tegoprazan, while Dr. Reddy's will oversee local clinical development, registration, marketing, and sales in the licensed territories. HK Inno.N. Corporation is a South Korea-based pharmaceutical company specializing in drugs for gastric ulcers.

Major companies operating in the gastric ulcers market are Pfizer Inc., Merck & Co Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Co. Ltd, Amgen Inc., Boehringer Ingelheim, Viatris Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd, Cadila Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Yuhan Corporation, Daewoong Pharmaceutical Co. Ltd, Cadila Healthcare Ltd, Novitium Pharma LLC

North America was the largest region in the gastric ulcers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric ulcers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the gastric ulcers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gastric ulcers market consists of revenues earned by entities through barium swallow, H. pylori testing, and biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastric ulcers market also includes sales of amoxicillin, clarithromycin, metronidazole, omeprazole, and lansoprazole. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gastric Ulcers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gastric ulcers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gastric ulcers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gastric ulcers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Proton Pump Inhibitors (PPI); H2 Antagonists; Antacids; Antibiotics; Cytoprotective Agents; Other Drug Classes
• 2) By Diagnosis: Stool Test; Endoscopy; Imaging Tests; Computed Tomography (CT) Scan; X-ray; Blood Tests; Other Diagnosis
• 3) By Route Of Administration: Oral; Parenteral; Other Route Of Administrations
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
• 5) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End Users
• Subsegments:
• 1) By Proton Pump Inhibitors (PPI): Omeprazole; Lansoprazole; Pantoprazole; Esomeprazole; Rabeprazole
• 2) By H2 Antagonists: Ranitidine; Famotidine; Cimetidine; Nizatidine
• 3) By Antacids: Calcium Carbonate; Magnesium Hydroxide; Aluminum Hydroxide; Sodium Bicarbonate
• 4) By Antibiotics: Amoxicillin; Clarithromycin; Metronidazole; Tetracycline
• 5) By Cytoprotective Agents: Sucralfate; Misoprostol; Bismuth Subsalicylate
• 6) By Other Drug Classes: Prostaglandin Analogues; Prokinetic Agents; Herbal And Alternative Medications; Combination Therapies
• Companies Mentioned: Pfizer Inc.; Merck & Co Inc.; AbbVie Inc.; Sanofi S.A.; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Gastric Ulcers Market Characteristics

3. Gastric Ulcers Market Trends And Strategies

4. Gastric Ulcers Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Gastric Ulcers Growth Analysis And Strategic Analysis Framework

• 5.1. Global Gastric Ulcers PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Gastric Ulcers Market Growth Rate Analysis
• 5.4. Global Gastric Ulcers Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Gastric Ulcers Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Gastric Ulcers Total Addressable Market (TAM)

6. Gastric Ulcers Market Segmentation

• 6.1. Global Gastric Ulcers Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Proton Pump Inhibitors (PPI)
• H2 Antagonists
• Antacids
• Antibiotics
• Cytoprotective Agents
• Other Drug Classes
• 6.2. Global Gastric Ulcers Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Stool Test
• Endoscopy
• Imaging Tests
• Computed Tomography (CT) Scan
• X-ray
• Blood Tests
• Other Diagnosis
• 6.3. Global Gastric Ulcers Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Route Of Administrations
• 6.4. Global Gastric Ulcers Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Distribution Channels
• 6.5. Global Gastric Ulcers Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End Users
• 6.6. Global Gastric Ulcers Market, Sub-Segmentation Of Proton Pump Inhibitors (PPI), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Omeprazole
• Lansoprazole
• Pantoprazole
• Esomeprazole
• Rabeprazole
• 6.7. Global Gastric Ulcers Market, Sub-Segmentation Of H2 Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ranitidine
• Famotidine
• Cimetidine
• Nizatidine
• 6.8. Global Gastric Ulcers Market, Sub-Segmentation Of Antacids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Calcium Carbonate
• Magnesium Hydroxide
• Aluminum Hydroxide
• Sodium Bicarbonate
• 6.9. Global Gastric Ulcers Market, Sub-Segmentation Of Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Amoxicillin
• Clarithromycin
• Metronidazole
• Tetracycline
• 6.10. Global Gastric Ulcers Market, Sub-Segmentation Of Cytoprotective Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sucralfate
• Misoprostol
• Bismuth Subsalicylate
• 6.11. Global Gastric Ulcers Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prostaglandin Analogues
• Prokinetic Agents
• Herbal And Alternative Medications
• Combination Therapies

7. Gastric Ulcers Market Regional And Country Analysis

• 7.1. Global Gastric Ulcers Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Gastric Ulcers Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Gastric Ulcers Market

• 8.1. Asia-Pacific Gastric Ulcers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Gastric Ulcers Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Gastric Ulcers Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Gastric Ulcers Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Gastric Ulcers Market

• 9.1. China Gastric Ulcers Market Overview
• 9.2. China Gastric Ulcers Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Gastric Ulcers Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Gastric Ulcers Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Gastric Ulcers Market

• 10.1. India Gastric Ulcers Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Gastric Ulcers Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Gastric Ulcers Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Gastric Ulcers Market

• 11.1. Japan Gastric Ulcers Market Overview
• 11.2. Japan Gastric Ulcers Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Gastric Ulcers Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Gastric Ulcers Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Gastric Ulcers Market

• 12.1. Australia Gastric Ulcers Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Gastric Ulcers Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Gastric Ulcers Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Gastric Ulcers Market

• 13.1. Indonesia Gastric Ulcers Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Gastric Ulcers Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Gastric Ulcers Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Gastric Ulcers Market

• 14.1. South Korea Gastric Ulcers Market Overview
• 14.2. South Korea Gastric Ulcers Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Gastric Ulcers Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Gastric Ulcers Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Gastric Ulcers Market

• 15.1. Western Europe Gastric Ulcers Market Overview
• 15.2. Western Europe Gastric Ulcers Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Gastric Ulcers Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Gastric Ulcers Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Gastric Ulcers Market

• 16.1. UK Gastric Ulcers Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Gastric Ulcers Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Gastric Ulcers Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Gastric Ulcers Market

• 17.1. Germany Gastric Ulcers Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Gastric Ulcers Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Gastric Ulcers Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Gastric Ulcers Market

• 18.1. France Gastric Ulcers Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Gastric Ulcers Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Gastric Ulcers Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Gastric Ulcers Market

• 19.1. Italy Gastric Ulcers Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Gastric Ulcers Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Gastric Ulcers Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Gastric Ulcers Market

• 20.1. Spain Gastric Ulcers Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Gastric Ulcers Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Gastric Ulcers Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Gastric Ulcers Market

• 21.1. Eastern Europe Gastric Ulcers Market Overview
• 21.2. Eastern Europe Gastric Ulcers Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Gastric Ulcers Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Gastric Ulcers Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Gastric Ulcers Market

• 22.1. Russia Gastric Ulcers Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Gastric Ulcers Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Gastric Ulcers Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Gastric Ulcers Market

• 23.1. North America Gastric Ulcers Market Overview
• 23.2. North America Gastric Ulcers Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Gastric Ulcers Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Gastric Ulcers Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Gastric Ulcers Market

• 24.1. USA Gastric Ulcers Market Overview
• 24.2. USA Gastric Ulcers Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Gastric Ulcers Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Gastric Ulcers Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Gastric Ulcers Market

• 25.1. Canada Gastric Ulcers Market Overview
• 25.2. Canada Gastric Ulcers Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Gastric Ulcers Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Gastric Ulcers Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Gastric Ulcers Market

• 26.1. South America Gastric Ulcers Market Overview
• 26.2. South America Gastric Ulcers Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Gastric Ulcers Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Gastric Ulcers Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Gastric Ulcers Market

• 27.1. Brazil Gastric Ulcers Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Gastric Ulcers Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Gastric Ulcers Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Gastric Ulcers Market

• 28.1. Middle East Gastric Ulcers Market Overview
• 28.2. Middle East Gastric Ulcers Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Gastric Ulcers Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Gastric Ulcers Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Gastric Ulcers Market

• 29.1. Africa Gastric Ulcers Market Overview
• 29.2. Africa Gastric Ulcers Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Gastric Ulcers Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Gastric Ulcers Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Gastric Ulcers Market Competitive Landscape And Company Profiles

• 30.1. Gastric Ulcers Market Competitive Landscape
• 30.2. Gastric Ulcers Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Gastric Ulcers Market Other Major And Innovative Companies

• 31.1. Abbott Laboratories
• 31.2. Novartis AG
• 31.3. GlaxoSmithKline plc
• 31.4. Takeda Pharmaceutical Co. Ltd
• 31.5. Amgen Inc.
• 31.6. Boehringer Ingelheim
• 31.7. Viatris Inc.
• 31.8. Daiichi Sankyo Company Limited
• 31.9. Eisai Co. Ltd
• 31.10. Cadila Pharmaceuticals
• 31.11. Dr. Reddy's Laboratories Ltd.
• 31.12. Hikma Pharmaceuticals PLC
• 31.13. Lupin Limited
• 31.14. Yuhan Corporation
• 31.15. Daewoong Pharmaceutical Co. Ltd

32. Global Gastric Ulcers Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gastric Ulcers Market

34. Recent Developments In The Gastric Ulcers Market

35. Gastric Ulcers Market High Potential Countries, Segments and Strategies

• 35.1 Gastric Ulcers Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Gastric Ulcers Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Gastric Ulcers Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer